The Remdesivir placebo-controlled randomized trial data.
We've eagerly awaited the data; now published @NEJM https://www.nejm.org/doi/pdf/10.1056/NEJMoa2007764?articleTools=true
Significant benefit for 27% time to recovery, across all subgroups except those on a ventilator/ECMO, death reduced 30% (95% CI 0.47, 1.04; NS)

The section about changing the primary endpoint and informing the NIAID. This seems perfectly above board, well done

The benefit in patients who were not ordinal scale 6/7 (on non-inv or invasive ventilation at baseline) is impressive. Safety issues were less with the drug v placebo
Overall remdesivir is a safe and effective drug for #COVID19 patients with lower respiratory tract involvement.

Review of the data supports the drug's potential for promoting survival.
For all patients enrolled, the 30% deaths is consistent in direction and magnitude as the 27% recovery time.
Patients w/ most severe baseline status derived no benefit.

A couple of weeks ago I summarized 4 drugs with preliminary encouraging results. Now we have a drug that unequivocally works to build on with combinations and/or better drugs to come. That's a big win, start for sick #COVID19 patients https://twitter.com/EricTopol/status/1259174745553002496